Several studies have discovered the pharmaceutical advancement in one or several features of BV, primarily focusing on pain-relieving (Lee et al., 2005), neuroprotective (Ye et al., 2016b), anti-inflammation (Jeong et al., 2017), enhancing wound recovery (Hozzein et al., 2018), anti-microbial impacts (El-Seedi et al., 2020), and cancer-fighting (Maek et al., 2023)
They have received approval from the U.S
Gabapentin (brand name Neurontin, among others) is FDA-approved for postherpetic neuralgia in adults and as adjunctive therapy for partial seizures in patients aged 3 and older [3]
Working with a qualified healthcare provider helps ensure that the right compounds, dosages, and protocols are selected
The fact that both cagrilintide and semaglutide have ~7-day half-lives is what makes CagriSema possible as a single weekly research protocol